The Associated Press @AP
After long delays, the FDA is expected to decide within weeks whether to authorize Novavax’s COVID-19 vaccine. The company is hoping to find a niche among some of the unvaccinated millions who might agree to a more traditional kind of shot: a protein vaccine. https://t.co/xMyByuOb2c — PolitiTweet.org